We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.37B
AUM Growth
+$301M
Cap. Flow
+$225M
Cap. Flow %
16.4%
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$31.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$15.5M
3
COLL icon
Collegium Pharmaceutical
COLL
+$13M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
5
ACHC icon
Acadia Healthcare
ACHC
+$10.7M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$22.5M
2
SRCL
Stericycle Inc
SRCL
+$10.3M
3
LH icon
Labcorp
LH
+$9.46M
4
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$7.97M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Financials 1.46%
3 Technology 0.96%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRNX
26
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$16.5M 1.2%
660,000
– –
ISRG icon
27
Intuitive Surgical
ISRG
$134B
$16M 1.17%
297,000
+94,500
+47% +$5.29M
INOV
28
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$15.6M 1.14%
560,000
+185,000
+49% +$4.97M
BIIB icon
29
Biogen
BIIB
$30.7B
$15.6M 1.14%
38,650
+1,650
+4% +$662K
CHRS icon
30
Coherus Oncology
CHRS
$196M
$15.4M 1.13%
534,000
+334,949
+168% +$8.47M
ADPT
31
DELISTED
Adeptus Health Inc
ADPT
$14.2M 1.04%
+150,000
New +$10.3M
COLL icon
32
Collegium Pharmaceutical
COLL
$956M
$13.5M 0.98%
+754,600
New +$13M
PRTA icon
33
Prothena Corp
PRTA
$459M
$13.2M 0.96%
250,000
+12,500
+5% +$493K
TMO icon
34
Thermo Fisher Scientific
TMO
$220B
$13M 0.95%
100,000
– –
RCPT
35
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$13M 0.95%
68,250
+3,250
+5% +$537K
TSRO
36
DELISTED
TESARO, Inc.
TSRO
$12.8M 0.93%
217,000
+7,000
+3% +$402K
SRGA
37
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$12M 0.88%
62,000
– –
EHC icon
38
Encompass Health
EHC
$12.4B
$11.9M 0.87%
323,678
+47,138
+17% +$1.68M
INCY icon
39
Incyte
INCY
$24.4B
$11.8M 0.86%
113,000
– –
HTWR
40
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$11.8M 0.86%
162,000
+57,000
+54% +$4.45M
KDNY
41
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$10.6M 0.77%
+70,000
New +$11.6M
JUNO
42
DELISTED
Juno Therapeutics, Inc.
JUNO
$10.5M 0.77%
197,000
+74,574
+61% +$3.96M
KYTH
43
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$10.5M 0.77%
139,250
+24,250
+21% +$1.3M
PRAH
44
DELISTED
PRA Health Sciences, Inc.
PRAH
$10.4M 0.76%
285,000
– –
MDCO
45
DELISTED
Medicines Co
MDCO
$9.88M 0.72%
345,500
+45,500
+15% +$1.27M
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
$9.75M 0.71%
1,100,000
+500,000
+83% +$4.73M
ARDX icon
47
Ardelyx
ARDX
$988M
$9.74M 0.71%
+610,000
New +$7.69M
DVA icon
48
DaVita
DVA
$11.7B
$9.7M 0.71%
122,050
+32,050
+36% +$2.63M
COO icon
49
Cooper Companies
COO
$14.5B
$9.61M 0.7%
216,000
– –
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.55B
$9.42M 0.69%
92,000
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rock Springs Capital Management held 130 positions worth $1.37B, up 28% from $1.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $225M of net new capital in Q2 2015, opening 25 new positions and adding to 53 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $6.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2015 buy was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.
  • Rock Springs Capital Management added most to Spark Therapeutics, Inc. Common Stock in Q2 2015, an estimated $31.4M increase.
  • Rock Springs Capital Management's biggest Q2 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $6.9M.
  • Rock Springs Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $22.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.37B portfolio in Q2 2015.
  • Rock Springs Capital Management opened 25 new positions and closed 13 in Q2 2015.
  • Rock Springs Capital Management's portfolio value rose 28% quarter-over-quarter to $1.37B.

Based on Rock Springs Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.